IP Library Patent Application 14261263
Patent Application
App. No. 14/261,263

METHOD OF MAKING A FORMULATION FOR DEACTIVATING NUCLEIC ACIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/261,263
Abstract

The disclosure relates to formulations for use in deactivating nucleic acids and methods of making and using the same.

Claims (29)

1 . A method of making a formulation for deactivating nucleic acids, the method comprising the steps of:

(a) separately dissolving solid forms of a corrosion-inhibiting agent and a wetting agent, the corrosion-inhibiting agent being phosphate, borate or sodium bicarbonate, and the wetting agent being a surfactant or detergent;

(b) combining together the dissolved forms of the corrosion-inhibiting agent and the wetting agent to form a first mixture;

(c) combining together the first mixture with a solubilizing agent to form a second mixture, the solubilizing agent being an organic solvent or an emulsifying agent; and

(d) instructing a user to combine the second mixture with a deactivating agent to form the formulation, the deactivating agent being sodium hypochlorite or dichloroisocyanurate,

whereby the concentration of the corrosion-inhibiting agent in the formulation is from about 10 mM to about 750 mM;

whereby the concentration of the wetting agent in the formulation is from about 0.005% to about 1% (w/v);

whereby the concentration of the solubilizing agent in the formulation is from about 0.001% to about 20% (v/v);

whereby the concentration of the deactivating agent in the formulation is from about 0.06% to about 3% (w/v) if the deactivating agent is sodium hypochlorite;

whereby the concentration of the deactivating agent in the formulation is from about 5 mM to about 400 mM if the deactivating agent is dichloroisocyanurate; and

whereby each agent of the formulation will remain substantially in solution at 22° C.

2 . The method of claim 1 , wherein the deactivating agent is sodium hypochlorite.

3 . The method of claim 2 , wherein the sodium hypochlorite is to be present in the formulation at a concentration of from about 0.18% to about 1.8% (w/v).

4 . The method of claim 2 , wherein the sodium hypochlorite is to be present in the formulation at a concentration of from about 0.6% to about 1.5% (w/v).

5 . The method of claim 2 , wherein the sodium hypochlorite is to be present in the formulation at a concentration of from about 0.6% to about 1.2% (w/v).

6 . The method of claim 1 , wherein the deactivating agent is dichloroisocyanurate.

7 . The method of claim 6 , wherein the dichloroisocyanurate is present in the formulation at a concentration of from about 10 mM to about 200 mM.

8 . The method of claim 6 , wherein the dichloroisocyanurate is present in the formulation at a concentration of from about 20 mM to about 100 mM.

9 . The method of claim 6 , wherein the dichloroisocyanurate is present in the formulation at a concentration of from about 40 mM to about 80 mM.

10 . The method of claim 1 , wherein the corrosion-inhibiting agent is sodium bicarbonate.

11 . The method of claim 1 , wherein the wetting agent is SDS or LLS.

12 . The method of claim 1 , wherein the solubilizing agent is an organic solvent.

13 . The method of claim 12 , wherein the organic solvent is benzyl acetate, polysorbate 20 (PS20), or isopropanol.

14 . The method of claim 1 , wherein the solubilizing agent is an emulsifying agent.

15 . The method of claim 14 , wherein the emulsifying agent is polyoxyethylene sortitan mono-palmitate, lecithin, or ethylene glycol distearate.

16 . The method of claim 1 , wherein the solubilizing agent is a fragrance.

17 . The method of claim 1 , further comprising dissolving a solid form of the solubilizing agent prior to step (c).

18 . The method of claim 1 , wherein the second mixture is 600 mM sodium bicarbonate, pH 9.3, 0.1% SDS, and 0.05% fragrance.

19 . The method of claim 1 , wherein the formulation is 0.6% sodium hypochlorite, 90 mM sodium bicarbonate, pH 9.3, 0.015 SDS, and 0.0075% fragrance.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL FRAME 033471 0102 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036126/0683 →
SECURITY INTEREST Recorded Aug 5, 2014
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 033471/0102 →